Guangzhou Releases First Batch of Innovative Drugs and Medical Devices List, Featuring Local Companies
The Guangzhou Municipal Industry and Information Technology Bureau has unveiled the first batch of innovative...
Policy / Regulatory
China’s NMPA Greenlights Pilot Plan for Phased Manufacturing of Biological Products
The National Medical Products Administration (NMPA) has given its stamp of approval to the “Pilot...
Tianjin Municipality Unveils Plan to Boost Synthetic Biology and Biomanufacturing Innovation
The People’s Government of Tianjin Municipality has unveiled two significant implementation plans to bolster the...
China’s NHSA Concludes Pre-Negotiation Talks for National Reimbursement Drug List
According to the Economic Observer, an independent Chinese weekly newsletter, a series of discussions preceding...
Chengdu Drafts Comprehensive Policy to Stimulate Biomedical Industry Growth
The Chengdu Municipal Bureau of Economic and Information Technology has unveiled a draft proposal titled...
NHSA Standardizes NRDL Drug Purchases to Combat Prescription Fraud
The National Healthcare Security Administration (NHSA) has issued a notification aimed at standardizing the management...
Shanxi Province Announces Historic Drug Procurement Batch with 81 Products for 2024
On October 16, 2024, Shanxi Province’s drug procurement platform announced a notice regarding the submission...
Beijing Aims to Build a Leading Cell and Gene Therapy Hub by 2026 with New Action Plan
The Beijing Municipal Science & Technology Commission, in conjunction with the Administrative Commission of Zhongguancun...
NMPA Sets Forthcoming Guidelines for Domestic Drug Refiling Procedures
The National Medical Products Administration (NMPA) has issued a notification outlining the requirements for the...
SAMR Proposes Guidelines to Curb Commercial Bribery in Pharmaceutical Industry
The State Administration for Market Regulation (SAMR) has unveiled the “Guidelines for Compliance of Pharmaceutical...
Guangdong Province Aims for RMB One Trillion in Biopharma Industry Growth by 2027
The People’s Government of Guangdong Province has unveiled an ambitious “Action Plan for Further Promoting...
China’s NMPA Proposes Rewards for Internal Whistleblowers in Drug and Medical Device Safety Reporting
The National Medical Products Administration (NMPA) of China has issued a draft proposal for the...
Shanghai Releases Local Guidelines to Correct Unhealthy Practices in Pharmaceutical Procurement and Medical Services
The Shanghai Municipal Health Commission, along with 13 other bureaus, has issued a local adaptation...
NMPA Expands Generic Quality Consistency Evaluation with 83rd Batch of Reference Drugs
The National Medical Products Administration (NMPA) in China has announced the release of the 83rd...
China’s National Healthcare Security Administration Issues Draft Guidelines for Long-Term Care Insurance
The National Healthcare Security Administration (NHSA) has released the “Draft Technical Guidelines for the Preparation...
China’s CDE Releases Draft Guidelines for Biosimilar Drug Labeling
On September 29, 2024, the Center for Drug Evaluation (CDE) of China’s National Medical Products...
Study Predicts 2025 Medicare Part D Negotiation Candidates, With Novo Nordisk’s Semaglutide Leading the List
Researchers in the U.S. have compiled a list of drugs that are anticipated to be...
China Sets New Management Measures for Investigator-Initiated Trials in Medical Institutions
The National Health Commission (NHC), National Administration of Traditional Chinese Medicine, and National Disease Control...
China Unveils Medical Insurance Eligibility Management System for Designated Healthcare Personnel
The National Healthcare Security Administration (NHSA), National Health Commission, and National Medical Products Administration (NMPA)...
Hunan Province Includes Fertility Treatments in Medical Insurance Coverage from October 2024
The Hunan Healthcare Security Administration has issued a notification to include specific assisted reproductive medical...